Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Inovio Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Prostate Cancer

Treatments: Device: Electroporation using CELLECTRA®-5P; Biological: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P; Biological: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P; Biological: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P; Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P

Study type: Interventional

Funder types: Industry

Identifiers

NCT02514213

PCa-001

Details and patient eligibility

About

This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.

Full description

Phase I, open label study of INO-5150 (DNA plasmids encoding prostate specific antigen (PSA) and prostate specific membrane antigen (PSMA)) alone or co-administered with INO-9012 (IL-12 plasmid) delivered intramuscularly followed by EP using the CELLECTRA®-5P device in adult males with biochemically relapsed prostate cancer following definitive local therapy (e.g. prostatectomy, external beam radiation, or brachytherapy). Four injections will be administered to approximately 60 eligible subjects who consent to participate in the study. Subjects will be monitored for safety and immunogenicity through Week 72.

Enrollment: 62 patients

Sex: Male

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men aged 18 to 90 years with a histologic diagnosis of prostate cancer;

2. c. Biochemical recurrence following local therapy, either surgery or radiation. Rising PSA defined as:

   • After definitive surgery, e.g.

     • After radical prostatectomy, two PSA measurements of ≥ 1.0 ng/mL at least one week apart;
     • After cryosurgery, two PSA measurements of ≥ 2.0 ng/mL at least one week apart;
     • Other definitive surgical procedures may be permissible upon the approval of the medical monitor OR

   • After radiation therapy (e.g., external beam radiation, brachytherapy, or salvage/adjuvant radiation therapy after surgery), two post radiation PSA measurements level of nadir plus 2.0 ng/mL at least one week apart.;

3. Serum testosterone level:

   i) Subjects with no history of androgen deprivation therapy:

   • A single measurement greater than 150 ng/dL or 5.2 nmol/L within 3 months of enrollment

   ii) Subjects with a history of androgen deprivation therapy (either in adjuvant or biochemical relapse setting):

   • The two most recent measurements of serum testosterone prior to enrollment must fulfill the following criteria:

     • Both measurements are greater than 150 ng/dL or 5.2 nmol/L;
     • The two measurements are spaced at least 14 days apart;
     • Both must be measured within 3 months of enrollment;

4. Normal electro cardio gram (ECG) or ECG with no clinically significant findings;

5. Adequate bone marrow, hepatic, and renal function tests within 30 days prior to enrollment:

   • CBC (except platelets and hemoglobin), serum chemistry, liver panel, and CPK values ≤ Grade 1 abnormality as defined in CTCAE v 4.03 dated June 14, 2010
   • Platelets ≥ 75,000 /mL;
   • Hemoglobin ≥ 9.0 g/dL;

6. No desire or plans to father new children during the study and/or have a prior vasectomy

Exclusion criteria

1. PSA doubling time (PSA-DT) of ≤ 3 months, using 2 PSA values at least 4 weeks apart, calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (https://www.mskcc.org/nomograms/prostate/psa-doubling-time);
2. Clinical or radiologic evidence of distant metastatic disease other than small volume (<1.5 cm) nodes, this should be tested within 12 months from enrollment;
3. Receipt of investigational therapy in a clinical trial setting within 30 days of enrollment;
4. Any pre-excitation syndromes, e.g., Wolff-Parkinson-White syndrome;
5. Prior major surgery or radiation therapy within 4 weeks of enrollment;
6. Any prior chemotherapy, except short-course neo-adjuvant or adjuvant chemotherapy that had been stopped for at least 6 weeks prior to Study enrollment;
7. Active AIDS / HIV infection, clinically uncontrolled immune deficiency disorders;
8. Clinically uncontrolled autoimmune disorders, transplant recipients who depend on immunosuppressive therapy, other immunosuppressive conditions including any concurrent condition requiring immunosuppressive/immunomodulating agents;
9. Recipient of any blood product and immunotherapy (such as anti-PD1, anti-PDL-1 and anti-CTLA4) within 3 months of enrollment;

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

62 participants in 4 patient groups

Arm A

Experimental group

Description:

2mg INO-5150 and electroporation device CELLECTRA®-5P

Treatment:

Device: Electroporation using CELLECTRA®-5P

Biological: 2mg INO-5150 and electroporation device CELLECTRA®-5P

Arm B

Experimental group

Description:

8.5mg INO-5150 and electroporation device CELLECTRA®-5P

Treatment:

Device: Electroporation using CELLECTRA®-5P

Biological: 8.5mg INO-5150 and electroporation device CELLECTRA®-5P

Arm C

Experimental group

Description:

2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

Treatment:

Device: Electroporation using CELLECTRA®-5P

Biological: 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

Arm D

Experimental group

Description:

8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P

Treatment:

Device: Electroporation using CELLECTRA®-5P

Biological: 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P